Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
500.27B
Market cap500.27B
Price-Earnings ratio
20.04
Price-Earnings ratio20.04
Dividend yield
2.48%
Dividend yield2.48%
Average volume
8.60M
Average volume8.60M
High today
$208.46
High today$208.46
Low today
$206.71
Low today$206.71
Open price
$207.73
Open price$207.73
Volume
2.32M
Volume2.32M
52 Week high
$215.19
52 Week high$215.19
52 Week low
$140.68
52 Week low$140.68

Stock Snapshot

Johnson & Johnson(JNJ) stock is priced at $207.63, giving the company a market capitalization of 500.27B. It carries a P/E multiple of 20.04 and pays a dividend yield of 2.5%.

On 2025-12-27, Johnson & Johnson(JNJ) stock moved within a range of $206.71 to $208.46. With shares now at $207.63, the stock is trading +0.4% above its intraday low and -0.4% below the session's peak.

Trading volume for Johnson & Johnson(JNJ) stock has reached 2.32M, versus its average volume of 8.6M.

The stock's 52-week range extends from a low of $140.68 to a high of $215.19.

The stock's 52-week range extends from a low of $140.68 to a high of $215.19.

JNJ News

Benzinga 2d
Johnson & Johnson Halts Atopic Dermatitis Study After Interim Analysis Miss

On Friday, Johnson & Johnson (NYSE:JNJ) shared the planned interim analysis from Phase 2b DUPLEX-AD proof-of-concept study of JNJ-95475939 for moderate to sever...

Nasdaq 2d
Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?

Johnson & Johnson JNJ, like any other large drugmaker, boasts a robust R&D pipeline of drugs, with its key focus areas being immunology, oncology and neuroscien...

Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
Nasdaq 3d
February 2026 Options Now Available For Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the February 2026 expiration. At Stock Options Channel , our YieldBoost fo...

February 2026 Options Now Available For Johnson & Johnson

Analyst ratings

56%

of 27 ratings
Buy
55.6%
Hold
40.7%
Sell
3.7%

More JNJ News

TipRanks 5d
Jury orders Johnson & Johnson to pay over $1.5B in talc case, Reuters says

A Baltimore jury has ordered Johnson & Johnson (JNJ) and its subsidiaries to pay more than $1.5B to a woman who said decades of exposure to asbestos in the comp...

TipRanks 5d
Johnson & Johnson issues statement on Craft verdict, intends to appeal

Erik Haas, worldwide VP of litigation, Johnson & Johnson said: “We will immediately appeal this egregious and patently unconstitutional verdict that is the dire...

The Wall Street Journal 5d
J&J Ordered to Pay Over $1.5 Billion in Talc Lawsuit

A Baltimore city jury ordered Johnson & Johnson to pay over $1.5 billion in a lawsuit that alleged the company’s talc-based personal products gave a Maryland wo...

J&J Ordered to Pay Over $1.5 Billion in Talc Lawsuit
Nasdaq 5d
The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years

Key Points Coca-Cola has increased its dividend for 63 straight years. Johnson & Johnson has matched Coca-Cola's dividend growth streak. Consolidated Edison...

The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years
Simply Wall St 5d
Johnson & Johnson: Has the Recent Rally Left the Healthcare Giant Undervalued?

Johnson & Johnson (JNJ) has quietly climbed about 17% over the past 3 months and roughly 44% year to date, putting the spotlight back on what investors are real...

Johnson & Johnson: Has the Recent Rally Left the Healthcare Giant Undervalued?
TipRanks 5d
Johnson & Johnson Faces $1.56 Billion Blow in Asbestos Lawsuit

A Maryland jury ordered Johnson & Johnson (JNJ) to pay about $1.56 billion to a woman who claimed the company’s talc-based baby powder caused her cancer. The ca...

Nasdaq 5d
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab)...

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.